Back to top
more

bioMerieux (BMXMF)

(Delayed Data from OTC)

$105.96 USD

105.96
45

-2.64 (-2.43%)

Updated Aug 2, 2024 11:19 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BMXMF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for bioMerieux falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 381 582 951 445 308
Receivables 1,022 977 900 834 749
Notes Receivable 0 0 0 0 0
Inventories 983 777 751 619 554
Other Current Assets 0 0 9 0 0
Total Current Assets 2,387 2,336 2,611 1,898 1,611
Net Property & Equipment 1,469 1,317 1,302 1,073 1,002
Investments & Advances 238 96 73 58 47
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 100 62 34 83 111
Intangibles 1,328 1,515 1,279 1,211 1,300
Deposits & Other Assets 8 14 15 16 18
Total Assets 5,692 5,465 5,462 4,487 4,236
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 287 284 283 237 237
Current Portion Long-Term Debt 177 197 118 147 491
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 57 52 80 51 36
Other Current Liabilities 656 659 650 621 546
Total Current Liabilities 1,177 1,192 1,131 1,055 1,311
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 56 72 121 158
Convertible Debt 0 0 0 0 0
Long-Term Debt 385 335 429 403 172
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 58 43 74 74 70
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,631 1,626 1,706 1,652 1,711
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 13 13 14 14 13
Capital Surplus 3,661 3,308 2,970 2,302 2,149
Retained Earnings 387 477 711 462 306
Other Equity 0 41 61 57 57
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 4,061 3,838 3,756 2,834 2,525
Total Liabilities & Shareholder's Equity 5,692 5,465 5,462 4,487 4,236
Total Common Equity 4,061 3,838 3,756 2,834 2,525
Shares Outstanding 118.30 118.30 118.30 118.30 118.30
Book Value Per Share 34.33 32.44 31.75 23.96 21.35

Fiscal Year End for bioMerieux falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 381 -99,999 -99,538
Receivables NA NA 1,022 NA 969
Notes Receivable NA NA 0 NA NA
Inventories NA NA 983 NA 917
Other Current Assets NA NA 0 NA NA
Total Current Assets NA NA 2,387 NA 2,347
Net Property & Equipment NA NA 1,469 NA 1,383
Investments & Advances NA NA 238 NA 97
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 100 NA 68
Intangibles NA NA 1,328 NA 1,447
Deposits & Other Assets NA NA 8 NA 8
Total Assets NA NA 5,692 NA 5,486
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA NA
Accounts Payable NA NA 287 NA 266
Current Portion Long-Term Debt NA NA 177 NA 175
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses NA NA 0 NA NA
Income Taxes Payable NA NA 57 NA 44
Other Current Liabilities NA NA 656 NA 584
Total Current Liabilities NA NA 1,177 NA 1,069
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 12 NA 37
Convertible Debt NA NA 0 NA NA
Long-Term Debt NA NA 385 NA 360
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 58 NA 49
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 1,631 NA 1,515
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) NA NA 13 NA 13
Capital Surplus NA NA 3,661 NA 3,766
Retained Earnings NA NA 387 NA 176
Other Equity NA NA 0 NA 15
Treasury Stock NA NA 0 NA NA
Total Shareholder's Equity NA NA 4,061 NA 3,971
Total Liabilities & Shareholder's Equity NA NA 5,692 NA 5,486
Total Common Equity 0 0 4,061 0 103,970
Shares Outstanding NA NA 118.30 118.30 118.30
Book Value Per Share 0.00 0.00 34.33 0.00 878.86